Coherus Oncology plans approximately 30% workforce cut
Coherus plans to focus for the next four or five quarters on growing LOQTORZI market share in relation to chemo-only treatment and off-label IO.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Coherus Oncology, Inc. (CHRS) reported third-quarter 2026 results and a strategic plan to focus tagmokitug/toripalimab development on esophageal cancer. Continuing-operations revenue was $14.3 million, versus $11.6 million a year earlier; continuing-operations net loss was $38.9 million, versus $44.5 million.
The company will continue first-line ESCC and second-line ESCC and EAC studies, deprioritize other cohorts, and seek FDA alignment on an expedited path initially focused on second-line esophageal cancer. For second-line ESCC/EAC cohorts, median progression-free survival was 5.5 months; in the 700 mg subgroup, clinical benefit rate was 55.6% and confirmed overall response rate was 33.3%. Data were as of October 14, 2026. The plan includes an approximately 30% workforce reduction.
Coherus said the changes will lower quarterly core cash burn by $6 million to $7 million over the next two quarters, with LOQTORZI revenue needed to cover core burn reduced to $25 million to $30 million from previously guided $30 million to $35 million. Cash, cash equivalents and marketable securities totaled $83.6 million as of September 30, 2026, versus $172.1 million as of December 31, 2025; balances included TSA-related collections to be applied to associated TSA payables and accrued liabilities.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQ3 continuing-operations revenue increased to $14.3 million from $11.6 million a year earlier.
- Moderate pointQ3 continuing-operations net loss narrowed to $38.9 million from $44.5 million in 2025.
Negative
- Major pointNine-month operating cash use was $153.995 million, versus $118.797 million in 2025.
Filing Explained
The third-quarter cash-flow statement reports completed proceeds of
8-K Event Classification
Key Figures
Key Terms
Clinical Benefit Rate (CBR) medical
confirmed Overall Response Rate (cORR) medical
Progression-Free Survival medical
regulatory T cells (Tregs) medical
non-GAAP net loss from continuing operations financial
Earnings Snapshot
Coherus said the benefits will be realized over the next two quarters, lowering quarterly core cash burn by $6 million to $7 million and the quarterly LOQTORZI revenue required to cover core burn to $25 million to $30 million, down from previously guided $30 million to $35 million.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue and net loss did CHRS report for Q3 2026?
What does Coherus exclude from non-GAAP net loss?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
| |||
(State or other jurisdiction |
| (Commission |
| (IRS Employer |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading | | Name of each exchange |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Conditions.
On November 9, 2026, Coherus Oncology, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.
This information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | | Description |
99.1 | Press release dated November 9, 2026. | |
104 | Cover page Interactive Data file (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 9, 2026 | | COHERUS ONCOLOGY, INC. | |
By: | /s/ Dennis M. Lanfear | ||
Name: | Dennis M. Lanfear | ||
Title: | Chief Executive Officer | ||
Exhibit 99.1
Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan
– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development –
– Deprioritize development of tagmokitug/toripalimab in other indications to allocate resources toward advancing the lead indication –
– Right-sizing reduces headcount by ~30%, aligning organization with forward-focused needs –
– Reports LOQTORZI® net revenue of $14.0 million in Q3 2026 –
– Conference call today at 5:00 p.m. Eastern Standard Time –
REDWOOD CITY, Calif., November 9, 2026 -- Coherus Oncology, Inc. (Nasdaq: CHRS) today reported financial results for the third quarter 2026 and provided an overview of recent business highlights.
“The strategic prioritization of esophageal cancer as our best-in-disease focus for tagmokitug, together with the Transition Services Agreement wind-down and the toripalimab process transfer completion, provides an ideal opportunity to right-size the organization and deliver financial benefits that flow directly from this prioritization,” said Denny Lanfear, Chief Executive Officer of Coherus Oncology. “Over the next four or five quarters we will remain intensely focused on growing LOQTORZI market share in relation to chemo-only, an inferior therapeutic approach, and off-label IO, which has not demonstrated standard-of-care level of benefit for patients living with nasopharyngeal carcinoma. We believe this approach can provide a path to financial self-sufficiency.”
“Esophageal cancers constitute difficult-to-treat tumors with significant unmet medical need. The compelling anti-tumor activity observed in both ESCC and EAC tumors suggests that Tregs are a critical driver of resistance. Importantly, we saw tagmokitug enhance PD-1’s activity, demonstrate activity in PD-L1 negative tumors, and rescue PD-1 refractory patients,” said Rosh Dias, M.D., Chief Medical Officer of Coherus Oncology. “Our immediate next step is to align with the FDA on our plans to expand the signal observed in esophageal cancer, with an initial focus on the second-line setting. This represents the fastest path to market in this underserved patient population.”
“The financial benefits of right-sizing the organization and reducing the scope of our forward-focused efforts provide substantial and durable benefits to our operating model,” said Bryan McMichael, Chief Financial Officer of Coherus Oncology. “These benefits will be realized over the next two quarters, lowering our core cash burn by $6 million to $7 million quarterly, which in turn lowers the quarterly LOQTORZI revenues required to cover core burn to $25 million to $30 million, down from $30 million to $35 million, as previously guided.”
RECENT BUSINESS HIGHLIGHTS
LOQTORZI® (toripalimab-tpzi) Commercial Updates
| ● | LOQTORZI revenue for Q3 2026 was $14.0 million, a 25% increase over $11.2 million in Q3 2025, and a 3% increase versus $13.6 million in Q2 2026. |
1
| ● | Demand continued to grow in the third quarter, driven by an increasing number of patients on therapy and increasing treatment duration. |
| ● | LOQTORZI remains the only FDA-approved and available treatment in the U.S. for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC). It is the only preferred Category 1 first-line treatment option recommended in combination with cisplatin and gemcitabine and the only preferred subsequent-line treatment recommended by the National Comprehensive Cancer Network® (NCCN). |
ADVANCEMENT OF INNOVATIVE, NEXT-GENERATION ONCOLOGY PIPELINE
Tagmokitug is a highly selective, cytolytic anti-CCR8 antibody designed to preferentially deplete CCR8-positive regulatory T cells (Tregs) in the tumor microenvironment, with the goal of overcoming immune resistance and enhancing antitumor immune responses. Tagmokitug is being evaluated in the TREGCHECK™ Phase 1b/2a clinical program in combination with toripalimab, with and without chemotherapy. As part of the strategic prioritization plan, Coherus will focus near-term tagmokitug development on esophageal cancer and deprioritize the other tagmokitug-toripalimab cohorts presented during our October 28, 2026, data release. The Company will continue ongoing first-line ESCC and second-line ESCC and EAC indications and pursue regulatory alignment on an expedited development path, initially focused on second-line esophageal cancer.
| ● | Enrollment remains ongoing in the Phase 1b cohorts evaluating tagmokitug in combination with toripalimab with or without chemotherapy in first- and second-line ESCC. The second-line EAC patients were enrolled as part of the upper gastrointestinal adenocarcinoma cohort, which has completed accrual and remains in follow-up. |
| ● | The overall interim clinical activity across second-line ESCC and second-line EAC of 22 treated and 13 evaluable patients demonstrated a confirmed ORR of 33.3% and a CBR of 55.6%. Coherus plans to initiate a new study evaluating tagmokitug in combination with toripalimab in patients with second line esophageal cancer (EAC and ESCC), an area of high unmet medical need. The Company intends to align with the FDA on the design of the new study and the proposed 700 mg dose, with the objective of pursuing an expedited development path. |
Figure 1. Second-line ESCC/EAC waterfall plot from TREGCHECK™ 102 Cohorts A (2L EAC) and B (2L ESCC). In the 700 mg dose sub-group, the Clinical Benefit Rate (CBR) was 55.6% and the confirmed Overall Response Rate (cORR) was 33.3%. Data as of October 14, 2026
2
Figure 2. Second-line ESCC/EAC swimmer plot from TREGCHECK™ 102 Cohorts A (2L EAC) and B (2L ESCC). Median Progression-Free Survival was 5.5 months. Data as of October 14, 2026
| ● | The Company plans to go forward with the Phase 1b clinical study evaluating tagmokitug in combination with pasritamig, a T-cell engaging bispecific antibody, in patients with metastatic castration-resistant prostate cancer (mCRPC), which is expected to initiate in the fall of 2026. |
Casdozokitug is a first-in-class IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line unresectable hepatocellular carcinoma (uHCC) to assess treatment benefit, safety, and response biomarkers.
| ● | Enrollment in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC is complete and the first data readout is expected in 1H 2027. |
THIRD QUARTER 2026 FINANCIAL RESULTS
Net revenue from continuing operations was $14.3 million and $11.6 million during the three months ended September 30, 2026 and 2025, respectively, and $40.9 million and $29.4 million during the nine months ended September 30, 2026 and 2025, respectively. The increases were driven primarily by volume growth of LOQTORZI.
Cost of goods sold (COGS) from continuing operations was $4.1 million and $3.7 million during the three months ended September 30, 2026 and 2025, respectively, and $12.1 million and $9.8 million during the nine months ended September 30, 2026 and 2025, respectively. The increases were primarily due to volume growth of LOQTORZI.
Research and development (R&D) expenses from continuing operations were $22.6 million and $27.3 million for the three months ended September 30, 2026 and 2025, respectively, and $65.6 million and $77.9 million during the nine months ended September 30, 2026 and 2025, respectively. The decreases were primarily due to savings from reduced headcount, lower infrastructure costs, and lower clinical trial and R&D manufacturing costs.
Selling, general and administrative (SG&A) expenses from continuing operations were $21.2 million and $24.9 million during the three months ended September 30, 2026 and 2025, respectively, and $65.3 million and $77.0 million during the nine months ended September 30, 2026 and 2025, respectively. The decreases were driven primarily by lower headcount and decreased operating costs resulting from Coherus completing the exit from the biosimilar business in 2025.
3
Net loss from continuing operations for the third quarter of 2026 was $38.9 million, or $(0.25) per share on a diluted basis, compared to $44.5 million, or $(0.38) per share on a diluted basis, for the same period in 2025. Net loss for the nine months ended September 2026 was $109.2 million, or $(0.73) per share on a diluted basis, compared to $136.8 million, or $(1.18) per share on a diluted basis for the same period of 2025.
Non-GAAP net loss from continuing operations for the third quarter of 2026 was $31.2 million, or $(0.20) per share on a diluted basis, compared to $38.9 million, or $(0.33) per share for the same period in 2025. Non-GAAP net loss for the nine months ended September 2026 was $95.3 million, or $(0.64) per share on a diluted basis, compared to $118.8 million, or $(1.02) per share for the same period in 2025. See “Non-GAAP Financial Measures” below for a discussion on how Coherus calculates non-GAAP net loss from continuing operations and a reconciliation to the most directly comparable GAAP measures.
Cash, cash equivalents and marketable securities totaled $83.6 million as of September 30, 2026, compared to $172.1 million as of December 31, 2025. These balances were inclusive of Transition Services Agreement (TSA)-related collections that will be applied to associated TSA payables and accrued liabilities which totaled $19.6 million and $65.1 million as of September 30, 2026 and December 31, 2025, respectively.
Conference Call Information
When: Monday, November 9, 2026, starting at 5:00 p.m. Eastern Standard Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BI55798b5af6004203b3a31cfe6dff187e
Webcast: https://edge.media-server.com/mmc/p/qhta3pue
A live and archived webcast will be available on the “Investors” section of the Coherus website at
https://investors.coherus.com/events-presentations
Please dial in 15 minutes early to ensure a timely connection to the call.
About Coherus Oncology
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting esophageal, liver, and prostate cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M nasopharyngeal carcinoma while advancing the development of its two pipeline candidates in combination with LOQTORZI, and additionally through strategic partnerships. The Company has global rights to both clinical-stage candidates and plans to execute ex-U.S. licensing deals as the clinical data support such transactions.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including gastroesophageal junction, esophageal adenocarcinoma, and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.
For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com
4
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, the ability of Coherus’ innovative oncology pipeline to enhance outcomes for cancer patients; the timing and results of anticipated clinical data results; Coherus’ ability to maintain and grow revenues; the effectiveness of Coherus’ cost reduction plan; and Coherus’ expectations about total addressable opportunity for LOQTORZI and for each of its product candidates.
Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to Coherus’ dependence on an ability to raise funds in the future, which may not be available on acceptable terms or at all; risks related to Coherus’ existing and potential collaboration partners; risks of Coherus’ competitive position with LOQTORZI and its product candidates; risks associated with Coherus’ ability to successfully commercialize and maintain and increase revenues for LOQTORZI; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of Coherus’ regulatory filings; the risk of FDA review issues; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2026 filed with the Securities and Exchange Commission on or about the date of this press release, including the section therein captioned “Risk Factors” and in other documents Coherus files with the Securities and Exchange Commission. Coherus’ results for the fiscal quarter ended September 30, 2026 are not necessarily indicative of its operating results for any future periods.
LOQTORZI®, whether or not appearing in large print or with the trademark symbol, is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.
Coherus Contact Information:
For Investors & Media:
Carrie Graham
Vice President, Investor Relations and Advocacy
IR@coherus.com
5
Coherus Oncology, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)
| | Three Months Ended | | Nine Months Ended | ||||||||
| | September 30, | | September 30, | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
Net revenue | | $ | 14,274 | | $ | 11,571 | | $ | 40,891 | | $ | 29,424 |
Costs and expenses: | |
| | |
| | |
| | |
| |
Cost of goods sold | |
| 4,092 | |
| 3,721 | |
| 12,148 | |
| 9,769 |
Research and development | |
| 22,606 | |
| 27,252 | |
| 65,591 | |
| 77,914 |
Selling, general and administrative | |
| 21,225 | |
| 24,931 | |
| 65,283 | |
| 76,995 |
Total costs and expenses | |
| 47,923 | |
| 55,904 | |
| 143,022 | |
| 164,678 |
Loss from operations | |
| (33,649) | |
| (44,333) | |
| (102,131) | | | (135,254) |
Interest expense | |
| (2,781) | |
| (2,325) | |
| (7,290) | |
| (6,752) |
Loss on debt extinguishment | | | (3,363) | | | — | | | (3,363) | | | — |
Other income (expense), net | |
| 918 | |
| 2,141 | |
| 3,627 | |
| 5,229 |
Loss from continuing operations before income taxes | |
| (38,875) | |
| (44,517) | |
| (109,157) | |
| (136,777) |
Income tax provision | |
| — | |
| — | |
| — | |
| — |
Net loss from continuing operations | | | (38,875) | | | (44,517) | | | (109,157) | | | (136,777) |
Net income (loss) from discontinued operations, net of tax | | | (459) | | | 8,986 | | | 10,865 | | | 342,444 |
Net income (loss) | | $ | (39,334) | | $ | (35,531) | | $ | (98,292) | | $ | 205,667 |
| | | | | | | | | | | | |
Net loss per share from continuing operations - basic and diluted | | $ | (0.25) | | $ | (0.38) | | $ | (0.73) | | $ | (1.18) |
Net income (loss) per share from discontinued operations - basic and diluted | | $ | — | | $ | 0.08 | | $ | 0.07 | | $ | 2.95 |
Net income (loss) per share - basic and diluted | | $ | (0.25) | | $ | (0.31) | | $ | (0.66) | | $ | 1.77 |
| | | | | | | | | | | | |
Weighted-average number of shares used in computing net income (loss) per share: | |
| | | | | |
| | | | |
Basic and diluted | | | 154,970,687 | | | 116,229,170 | | | 148,796,665 | | | 116,056,247 |
6
Coherus Oncology, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
| | September 30, | | December 31, | ||
| | 2026 | | 2025 | ||
Assets |
| | |
| | |
Cash and cash equivalents |
| $ | 53,487 | | $ | 88,879 |
Investments in marketable securities | | | 30,142 | | | 83,246 |
Trade receivables, net | | | 13,720 | | | 17,815 |
Inventory | | | 14,178 | |
| 3,172 |
Intangible assets, net | | | 44,364 | | | 46,239 |
Other assets | | | 15,213 | | | 18,992 |
Total assets | | $ | 171,104 | | $ | 258,343 |
| | | | | | |
Liabilities and Stockholders’ Equity | |
| | |
| |
Accrued rebates, fees and reserve | | $ | 13,746 | | $ | 30,397 |
TSA payables and accrued liabilities | | | 19,638 | | | 65,065 |
Term loans | | | 52,551 | | | 37,051 |
Other liabilities | |
| 59,920 | |
| 64,816 |
Total stockholders' equity | |
| 25,249 | | | 61,014 |
Total liabilities and stockholders’ equity | | $ | 171,104 | | $ | 258,343 |
7
Coherus Oncology, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
| | Three Months Ended | | Nine Months Ended | ||||||||
| | September 30, | | September 30, | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
Cash, cash equivalents and restricted cash at beginning of the period | | $ | 83,163 | | $ | 217,156 | | $ | 89,119 | | $ | 126,250 |
| |
| | |
| | |
| | |
| |
Net cash used in operating activities | |
| (34,019) | |
| (46,339) | |
| (153,995) | |
| (118,797) |
| |
| | |
| | |
| | |
| |
Purchases of investments in marketable securities | | | (30,064) | | | (68,850) | | | (50,349) | | | (89,576) |
Proceeds from maturities of investments in marketable securities | | | 22,455 | | | 1,650 | | | 104,126 | | | 1,650 |
Net cash received related to the Sale Transactions | | | — | | | — | | | — | | | 478,681 |
Milestone payment to Junshi Biosciences | | | — | | | — | | | — | | | (12,500) |
Other investing activities, net | |
| — | |
| (27) | |
| (1,100) | |
| (330) |
Net cash (used in) provided by investing activities | |
| (7,609) | |
| (67,227) | |
| 52,677 | |
| 377,925 |
| |
| | |
| | |
| | |
| |
Proceeds from 2031 Term Loan, net of discount and issuance costs | | | 52,657 | | | — | | | 52,657 | | | — |
Proceeds from issuance of common stock under Public Offering, net of issuance costs | | | — | | | — | | | 53,650 | | | — |
Partial repayment of Revenue Purchase and Sale Agreement | | | — | | | — | | | — | | | (47,652) |
Proceeds from purchases under the employee stock purchase plan | | | — | | | — | | | 202 | | | 188 |
Repayment and redemption of 2026 Convertible Notes, including transaction costs | | | — | | | — | | | (121) | | | (233,185) |
Repayment of 2029 Term Loan, including premiums and fees | | | (40,661) | | | — | | | (40,661) | | | — |
Other financing activities, net | | | 50 | | | 2 | | | 53 | | | (1,137) |
Net cash provided by (used in) financing activities | |
| 12,046 | |
| 2 | |
| 65,780 | |
| (281,786) |
| |
| | |
| | |
| | |
| |
Net decrease in cash, cash equivalents and restricted cash | |
| (29,582) | | | (113,564) | |
| (35,538) | |
| (22,658) |
| | | | | | | | | | | | |
Cash, cash equivalents and restricted cash at end of the period | | $ | 53,581 | | $ | 103,592 | | $ | 53,581 | | $ | 103,592 |
8
Non-GAAP Financial Measures
To supplement the financial results presented in accordance with GAAP, Coherus has included in this press release non-GAAP net loss from continuing operations, and the related per share measures, which exclude from net loss from continuing operations and the related per share measures, stock-based compensation expense, amortization and impairments of intangible assets, loss on debt extinguishment, and change in fair value of our derivative liabilities. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. Coherus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand Coherus’ business.
Coherus believes that the presentation of these non-GAAP financial measures provides useful supplemental information to, and facilitates additional analysis by, investors. In particular, Coherus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare Coherus’ results from period to period, and to identify operating trends in Coherus’ business. Coherus also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.
Coherus Oncology, Inc.
Reconciliation of GAAP Net Loss from Continuing Operations to Non-GAAP Net Loss from Continuing Operations
(in thousands, except share and per share data)
(unaudited)
| | Three Months Ended | | Nine Months Ended | ||||||||
| | September 30, | | September 30, | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
GAAP net loss from continuing operations | | $ | (38,875) | | $ | (44,517) | | $ | (109,157) | | $ | (136,777) |
Adjustments: | | | | | | | | | | | | |
Stock-based compensation expense | | | 3,682 | | | 3,322 | | | 8,650 | | | 13,535 |
Loss on debt extinguishment | | | 3,363 | | | — | | | 3,363 | | | — |
Impairment of out-license asset, net | | | — | | | 1,646 | | | — | | | 1,646 |
Change in fair value of derivative liabilities | | | — | | | — | | | — | | | 810 |
Amortization of intangible assets | | | 625 | | | 652 | | | 1,875 | | | 1,986 |
Non-GAAP net loss from continuing operations | | $ | (31,205) | | $ | (38,897) | | $ | (95,269) | | $ | (118,800) |
| | | | | | | | | | | | |
GAAP | | | | | | | | | | | | |
Net loss per share from continuing operations, basic and diluted | | $ | (0.25) | | $ | (0.38) | | $ | (0.73) | | $ | (1.18) |
Shares used in computing basic and diluted net loss per share | | | 154,970,687 | | | 116,229,170 | | | 148,796,665 | | | 116,056,247 |
| | | | | | | | | | | | |
Non-GAAP | | | | | | | | | | | | |
Net loss per share from continuing operations, basic and diluted | | $ | (0.20) | | $ | (0.33) | | $ | (0.64) | | $ | (1.02) |
Shares used in computing basic and diluted net loss per share | | | 154,970,687 | | | 116,229,170 | | | 148,796,665 | | | 116,056,247 |
9